Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis

Trial Profile

A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs BLD-2660 (Primary)
  • Indications Fibrosis; Hepatic fibrosis; Pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Blade Therapeutics
  • Most Recent Events

    • 14 Jan 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
    • 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
    • 17 Jul 2018 According to a Blade Therapeutics media release, results are expected by the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top